UNSPSC 51372108: Oxycodone

This classification denotes an opioid receptor agonist and opioid with the molecular formula C18H21NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CD35PMG570, chemically known as 4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one but generally known as oxycodone, which bears US NIH Compound Identifier 5284603. European Medicines Agency schedules Oxycodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09562MIG. The term OXYCODONE is an International Non-Proprietary Name.

UNSPSC 51372108 Oxycodone is a Commodity code that captures pharmaceutical procurement by state and local health agencies, though recent solicitations show minimal direct oxycodone purchases and instead reflect broader pharmaceutical supply management, harm-reduction product acquisition, and multi-source generic drug contracting. State and local governments use this code primarily to procure controlled pharmaceutical products through health departments, corrections systems, emergency medical services, and community health initiatives, often bundled with purchasing agreements that span multiple drug categories and suppliers. Issuing bodies include state health and human services commissions operating multistate cooperative purchasing vehicles, county health departments managing community health programs, and state procurement offices administering centralized pharmacy benefit contracts. The Texas Health and Human Services Commission and Minnesota Department of Administration represent major repeat actors in recent activity, with both pursuing statewide or multistate pharmaceutical contracting frameworks rather than single-drug buys.

Activity concentrates in Texas, Florida, and Minnesota. The Seminole County, Florida health department issued an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries to support community health initiatives and potential FEMA funding. The Texas Health and Human Services Commission posted an RFI (HHS0017013, due April 3, 2026) exploring vendor capacity for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking direct relationships between state pharmacy benefit programs and manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802, due March 26, 2026) for multiple contracts supplying generic multi-source pharmaceuticals and OTC products to participating state and local facilities across Minnesota and Oregon, requiring vendors to work through three authorized wholesalers and meet cGMP and Drug Supply Chain Security Act certifications.